TAKEDA PHARMACEUTIC-SP ADR

Takeda’s oral TYK2 inhibitor zasocitinib outperforms Bristol Myers Squibb’s therapy in a Phase III study, achieving higher PASI‑90/100 rates, faster onset, and a comparable safety profile for moderate‑to‑severe plaque psoriasis.

Takeda partners on IBI363, a lung‑cancer therapy, to hit unmet NSCLC needs with a 3‑year payback and 150% ROI, boosting its oncology pipeline and M&A prospects.